Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 16.38
+0.25 (1.55%)
At close: Feb 13, 2026
SHE:300497 Revenue
Jiangxi Fushine Pharmaceutical had revenue of 254.68M CNY in the quarter ending September 30, 2025, a decrease of -13.51%. This brings the company's revenue in the last twelve months to 970.32M, down -25.37% year-over-year. In the year 2024, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B, down -26.83%.
Revenue (ttm)
970.32M
Revenue Growth
-25.37%
P/S Ratio
9.09
Revenue / Employee
546.97K
Employees
1,774
Market Cap
8.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.18B | -431.82M | -26.83% |
| Dec 31, 2023 | 1.61B | -37.59M | -2.28% |
| Jan 1, 2023 | 1.65B | 217.72M | 15.23% |
| Jan 1, 2022 | 1.43B | -63.41M | -4.25% |
| Dec 31, 2020 | 1.49B | 138.91M | 10.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.83B |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Youcare Pharmaceutical Group | 2.55B |
| Nanjing Vazyme Biotech | 1.34B |
| Chengdu Kanghua Biological Products | 1.21B |
| Shanghai Medicilon | 1.08B |
| Acrobiosystems | 794.52M |
| R&G PharmaStudies | 789.45M |